Clinical trials recruiting in Ravensburg, Germany

Phase breakdown

Conditions recruiting in Ravensburg, Germany

Recruiting trials in Ravensburg, Germany

• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
  NCT06830720 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
  NCT07237256 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
  NCT06207734 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
  NCT07563595 · Phase: Not specified · Ages: 18 Years and older · Sex: Female
• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
  NCT06201234 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
  NCT06722183 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
  NCT06494540 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female)
• PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
  NCT05792150 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: Female
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
  NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
  NCT05008809 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Ravensburg, Germany?

17 recruiting trials have at least one study site in Ravensburg, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.